Brian Park, PharmD

Drug Information Specialist https://www.renalandurologynews.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Men's Health Update

Remdesivir Distribution Transitioned to Gilead Under Revised EUA

Brian Park, PharmD

October 8, 2020

By increasing manufacturing capacity, Gilead has been able to expand the supply of remdesivir, which now exceeds market demand.

Chronic Kidney Disease (CKD)

Dapagliflozin Gets Breakthrough Therapy Status for CKD Indication

Brian Park, PharmD

October 7, 2020

The designation was granted based on results from the phase 3 DAPA-CKD trial, which was stopped early due to “overwhelming efficacy”.

Men's Health Update

Moderna’s COVID-19 Vaccine Candidate Elicits Immune Response in Older Adults

Brian Park, PharmD

October 2, 2020

Interim data showed that both doses of mRNA-1273 elicited strong immune responses in older adults.

Cardiovascular Disease (CVD)

Empagliflozin Fast Tracked for Improving Outcomes Following Myocardial Infarction

Brian Park, PharmD

September 21, 2020

The effect of empagliflozin on all-cause mortality and hospitalization for heart failure will be evaluated in the in phase 3 EMPACT-MI study.

Hyperphosphatemia

Tenapanor Under Review for Hyperphosphatemia in CKD

Brian Park, PharmD

September 18, 2020

Tenapanor is a first-in-class oral medication that works by blocking the NHE3 transporter in the gastrointestinal tract.

Nephrology

FDA Rejects Terlipressin NDA for Hepatorenal Syndrome Type 1

Brian Park, PharmD

September 17, 2020

In July 2020, the FDA Cardiovascular and Renal Drugs Advisory Committee narrowly voted 8 to 7 in favor of the approval of terlipressin for HRS-1.

Men's Health Update

Baricitinib Plus Remdesivir Cuts Time to Recovery for Hospitalized COVID-19 Patients

Brian Park, PharmD

September 16, 2020

The ACTT-2 study began on May 8 and included more than 1000 patients.

Men's Health Update

Trial Evaluating Half-Life Extended Monoclonal Antibodies for COVID-19 Begins

Brian Park, PharmD

September 10, 2020

The trial will include up to 48 healthy participants in the UK.

Diabetic Nephropathy

Boxed Warning Removed From Canagliflozin Labeling

Brian Park, PharmD

August 28, 2020

The FDA concluded “the risk no longer meets the standard for a Boxed Warning.”

Chronic Kidney Disease (CKD)

FDA Cites Deficiencies in Veverimer NDA for Metabolic Acidosis in CKD

Brian Park, PharmD

August 26, 2020

Veverimer is a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD.

Next post in Chronic Kidney Disease (CKD)